About this Journal Submit a Manuscript Table of Contents
Journal of Obesity
Volume 2011 (2011), Article ID 946795, 7 pages
http://dx.doi.org/10.1155/2011/946795
Research Article

Serum Neopterin Is Not Increased in Obese Juveniles

1Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036 Graz, Austria
2Department of Pediatrics, University Hospital of Salzburg, 5020 Salzburg, Austria
3Division of Biological Chemistry, Biocenter, Innsbruck Medical University, 6020 Innsbruck, Austria

Received 11 June 2010; Accepted 22 December 2010

Academic Editor: A. Halpern

Copyright © 2011 Harald Mangge et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. K. Hansson, “Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1685–1626, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. Vonhof, B. Brost, M. Stille-Siegener, I. M. Grumbach, H. Kreuzer, and H. R. Figulla, “Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy,” International Journal of Cardiology, vol. 63, no. 3, pp. 237–244, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Tatzber, H. Rabl, and H. Rabl, “Elevated serum neopterin levels in atherosclerosis,” Atherosclerosis, vol. 89, no. 2-3, pp. 203–208, 1991. View at Scopus
  4. G. Weiss, J. Willeit, and J. Willeit, “Increased concentrations of neopterin in carotid atherosclerosis,” Atherosclerosis, vol. 106, no. 2, pp. 263–271, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Schumacher, G. Halwachs, and G. Halwachs, “Increased neopterin in patients with chronic and acute coronary syndromes,” Journal of the American College of Cardiology, vol. 30, no. 3, pp. 703–707, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. E. P. Gurfinkel, B. M. Scirica, G. Bozovich, A. Macchia, E. Manos, and B. Mautner, “Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction,” American Journal of Cardiology, vol. 83, no. 4, pp. 515–518, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Kiechl, E. Lorenz, and E. Lorenz, “Toll-like receptor 4 polymorphisms and atherogenesis,” The New England Journal of Medicine, vol. 347, no. 3, pp. 185–192, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. E. Zouridakis, P. Avanzas, R. Arroyo-Espliguero, S. Fredericks, and J. C. Kaski, “Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris,” Circulation, vol. 110, no. 13, pp. 1747–1753, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. P. Avanzas, R. Arroyo-Espliguero, J. Quiles, D. Roy, and J. C. Kaski, “Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris,” European Heart Journal, vol. 26, no. 5, pp. 457–463, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, and M. Garcia-Gonzalez, “Usefulness of neopterin levels and left ventricular function for risk assessment in survivors of acute myocardial infarction,” International Journal of Cardiology, vol. 111, no. 2, pp. 318–320, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. D. T. Johnston, M. Gagos, N. Raio, L. Ragolia, D. Shenouda, M. A. Davis-Lorton, and J. R. De Leon, “Alterations in serum neopterin correlate with thrombolysis in myocardial infarction risk scores in acute coronary syndromes,” Coronary Artery Disease, vol. 17, no. 6, pp. 511–516, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. K. K. Ray, D. A. Morrow, M. S. Sabatine, A. Shui, N. Rifai, C. P. Cannon, and E. Braunwald, “Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome,” Circulation, vol. 115, no. 24, pp. 3071–3078, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. T. Adachi, T. Naruko, and T. Naruko, “Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions,” Heart, vol. 93, no. 12, pp. 1537–1541, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. C. Kaski, L. Consuegra-Sanchez, and L. Consuegra-Sanchez, “Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome,” Atherosclerosis, vol. 201, no. 1, pp. 176–183, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. H. F. Alber, C. Duftner, and C. Duftner, “Neopterin, CD4+CD28 lymphocytes and the extent and severity of coronary artery disease,” International Journal of Cardiology, vol. 135, no. 1, pp. 27–35, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. V. Videm, R. Wiseth, S. Gunnes, H. O. Madsen, and P. Garred, “Multiple inflammatory markers in patients with significant coronary artery disease,” International Journal of Cardiology, vol. 118, no. 1, pp. 81–87, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. T. B. Grammer, D. Fuchs, B. O. Boehm, B. R. Winkelmann, and W. Maerz, “Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study,” Clinical Chemistry, vol. 55, no. 6, pp. 1135–1146, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. I. T. Vengen, A. C. Dale, R. Wiseth, K. Midthjell, and V. Videm, “Neopterin predicts the risk for fatal ischemic heart disease in type 2 diabetes mellitus. Long-term follow-up of the HUNT 1 study,” Atherosclerosis, vol. 207, no. 1, pp. 239–244, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. C. Huber, J. R. Batchelor, and D. Fuchs, “Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma,” Journal of Experimental Medicine, vol. 160, no. 1, pp. 310–316, 1984. View at Scopus
  20. B. Wirleitner, D. Reider, and D. Reider, “Monocyte-derived dendritic cells release neopterin,” Journal of Leukocyte Biology, vol. 72, no. 6, pp. 1148–1153, 2002. View at Scopus
  21. C. Murr, B. Widner, B. Wirleitner, and D. Fuchs, “Neopterin as a marker for immune system activation,” Current Drug Metabolism, vol. 3, no. 2, pp. 175–187, 2002. View at Scopus
  22. D. Fuchs, G. Weiss, G. Reibnegger, and H. Wachter, “The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases,” Critical Reviews in Clinical Laboratory Sciences, vol. 29, no. 3-4, pp. 307–341, 1992. View at Scopus
  23. C. Murr, A. Bergant, M. Widschwendter, K. Heim, H. Schröcksnadel, and D. Fuchs, “Neopterin is an independent prognostic variable in females with breast cancer,” Clinical Chemistry, vol. 45, no. 11, pp. 1998–2004, 1999. View at Scopus
  24. G. Reibnegger, C. Aichberger, and C. Aichberger, “Posttransplant neopterin excretion in renal allograft recipients—a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival,” Transplantation, vol. 52, no. 1, pp. 58–63, 1991. View at Scopus
  25. H. Mangge, K. Schauenstein, L. Stroedter, A. Griesl, W. Maerz, and M. Borkenstein, “Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis,” Experimental and Clinical Endocrinology and Diabetes, vol. 112, no. 7, pp. 378–382, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. S. Pilz, R. Horejsi, and R. Horejsi, “Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 8, pp. 4792–4796, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. H. Mangge, G. Almer, and G. Almer, “Nuchal thickness of subcutaneous adipose tissue is tightly associated with an increased LMW/total adiponectin ratio in obese juveniles,” Atherosclerosis, vol. 203, no. 1, pp. 277–283, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. M. Ledochowski, C. Murr, B. Widner, and D. Fuchs, “Association between insulin resistance, body mass and neopterin concentrations,” Clinica Chimica Acta, vol. 282, no. 1-2, pp. 115–123, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Kiechl and J. Willeit, “The natural course of atherosclerosis: part II: vascular remodeling,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 6, pp. 1491–1498, 1999.
  30. R. Moeller, R. Horejsi, and R. Horejsi, “Evaluation of risk profiles by subcutaneous adipose tissue topography in obese juveniles,” Obesity, vol. 15, no. 5, pp. 1319–1324, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. B. R. Winkelmann, W. März, B. O. Boehm, R. Zotz, J. Hager, P. Hellstern, and J. Senges, “Rationale and design of the LURIC study—a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease,” Pharmacogenomics, vol. 2, supplement 1, pp. S1–S73, 2001. View at Scopus
  32. P. L. van Haelst, A. Liem, and A. Liem, “Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction,” American Journal of Cardiology, vol. 92, no. 10, pp. 1201–1203, 2003. View at Publisher · View at Google Scholar
  33. P. Cirillo, M. Pacileo, and M. Pacileo, “Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells,” Journal of Thrombosis and Haemostasis, vol. 4, no. 10, pp. 2248–2255, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. J. Auer, R. Berent, E. Laßnig, and B. Eber, “Serum neopterin and activity of coronary artery disease,” Heart Disease, vol. 3, no. 5, pp. 297–301, 2001.
  35. G. Hoffmann, W. Schobersberger, and W. Schobersberger, “Neopterin activates transcription factor nuclear factor-κB in vascular smooth muscle cells,” FEBS Letters, vol. 391, no. 1-2, pp. 181–184, 1996. View at Publisher · View at Google Scholar
  36. D. Fuchs, P. Avanzas, R. Arroyo-Espliguero, M. Jenny, L. Consuegra-Sanchez, and J. C. Kaski, “The role of neopterin in atherogenesis and cardiovascular risk assessment,” Current Medicinal Chemistry, vol. 16, no. 35, pp. 4644–4653, 2009. View at Publisher · View at Google Scholar
  37. G. Weiss, C. Murr, H. Zoller, M. Haun, B. Widner, C. Ludescher, and D. Fuchs, “Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells,” Clinical and Experimental Immunology, vol. 116, no. 3, pp. 435–440, 1999. View at Publisher · View at Google Scholar
  38. P. Mayersbach, D. Fuchs, and H. Schennach, “Performance of a fully automated quantitative neopterin measurement assay in a routine voluntary blood donation setting,” Clinical Chemistry and Laboratory Medicine, vol. 48, no. 3, pp. 373–377, 2010. View at Publisher · View at Google Scholar · View at PubMed
  39. M. Jenny, M. Klieber, and M. Klieber, “In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors,” Inflammation Research. In press. View at Publisher · View at Google Scholar · View at PubMed
  40. H. Sprenger, C. Jacobs, M. Nain, A. M. Gressner, H. Prinz, W. Wesemann, and D. Gemsa, “Enhanced release of cytokines, interleukin-2 receptors, and neopterin after long-distance running,” Clinical Immunology and Immunopathology, vol. 63, no. 2, pp. 188–195, 1992. View at Publisher · View at Google Scholar
  41. G. P. Tilz, W. Domej, and W. Domej, “Increased immune activation during and after physical excercise,” Immunobiology, vol. 188, no. 1-2, pp. 194–202, 1993.
  42. M. Ristow, K. Zarse, and K. Zarse, “Antioxidants prevent health-promoting effects of physical exercise in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 21, pp. 8665–8670, 2009. View at Publisher · View at Google Scholar · View at PubMed
  43. J. Sun, G. K. Sukhova, and G. K. Sukhova, “Mast cells promote atherosclerosis by releasing proinflammatory cytokines,” Nature Medicine, vol. 13, no. 6, pp. 719–724, 2007. View at Publisher · View at Google Scholar · View at PubMed